Ostovar Rahim, Kiani Faezeh, Sayehmiri Fatemeh, Yasemi Masood, Mohsenzadeh Yazdan, Mohsenzadeh Yousof
PhD, Associate Professor, Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Msc, Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran.
Electron Physician. 2017 Oct 25;9(10):5402-5418. doi: 10.19082/5402. eCollection 2017 Oct.
Metabolic syndrome) MetS( is a complex risk factor which increases the risk of cardiovascular diseases and type 2 diabetes. There are many studies with various populations and results about the prevalence of MetS in Iran; in order to authenticate these studies and have an overall estimation of its prevalence in Iran, performing a meta-analysis seems to be necessary.
This study aimed to investigate the prevalence of MetS and its components in Iran via meta-analysis method.
All associated published papers in national and international journals of PubMed, Scopus, Web of Science, Magiran, Iranmedex, Science Direct, Medlib, and SID databases were searched from January, 2000 to October, 2016. All types of studies, including local and national surveys that reported the prevalence of MetS among healthy populations in Iran were reviewed. The effects of age, sample size and publication date as possible sources of heterogeneity among the study findings was examined by meta-regression. P-values less than 0.05 were considered as significant in heterogeneity tests. All analysis was done by R Ver. 3.2.1 and STATA (version 10).
Seventy eligible studies were selected for meta-analysis. The overall estimation of MetS prevalence was 25% (95% CI: 22-29%) based on the Adult Treatment Panel III (ATP III) criteria, 30% (95% CI: 25-36%) according to the International Diabetes Federation (IDF), and 39% (95% CI: 26-52%) based on the Joint Interim Societies (JIS) criteria. The prevalence of MetS was lower in men than in women (26.9% versus 35.7%). The prevalence of various MetS components including High TG (triglyceride), Low HDL-C, High BP and High FBS (fasting blood sugar) was 43%, 54%, 38% and 22% among the adult population.
Findings from the present meta-analyses study displayed a high prevalence of metabolic syndrome in Iran, especially in women, which increases with age in both sexes. It alerts health care providers and policy makers to find solutions in order to take action to reduce MetS risk in society.
代谢综合征(MetS)是一种复杂的风险因素,会增加心血管疾病和2型糖尿病的发病风险。关于伊朗代谢综合征患病率,已有许多针对不同人群并得出不同结果的研究;为了验证这些研究并全面估计其在伊朗的患病率,进行一项荟萃分析似乎很有必要。
本研究旨在通过荟萃分析方法调查伊朗代谢综合征及其各组分的患病率。
检索了2000年1月至2016年10月期间PubMed、Scopus、科学网、Magiran、Iranmedex、Science Direct、Medlib和SID数据库中国内外期刊上所有相关的已发表论文。对所有类型的研究进行了综述,包括报告伊朗健康人群中代谢综合征患病率的地方和全国性调查。通过荟萃回归分析年龄、样本量和发表日期作为研究结果中可能的异质性来源的影响。在异质性检验中,P值小于0.05被认为具有统计学意义。所有分析均使用R Ver. 3.2.1和STATA(版本10)完成。
70项符合条件的研究被选入荟萃分析。根据成人治疗小组第三次报告(ATP III)标准,代谢综合征患病率的总体估计为25%(95%可信区间:22 - 29%),根据国际糖尿病联盟(IDF)为30%(95%可信区间:25 - 36%),根据联合临时学会(JIS)标准为39%(95%可信区间:26 - 52%)。男性代谢综合征患病率低于女性(26.9%对35.7%)。在成年人群中,代谢综合征各组分的患病率,包括高甘油三酯(TG)、低高密度脂蛋白胆固醇(HDL - C)、高血压(BP)和高空腹血糖(FBS)分别为43%、54%、38%和22%。
本荟萃分析研究结果显示,伊朗代谢综合征患病率较高,尤其是女性,且男女患病率均随年龄增长而增加。这提醒医疗保健提供者和政策制定者寻找解决方案,以便采取行动降低社会中代谢综合征风险。